Added to YB: 2025-03-27
Pitch date: 2025-03-25
NTLA [bullish]
Intellia Therapeutics, Inc.
+43.01%
current return
Author Info
Golden Bear Capital is where swing trading meets deep research. Sign up for the newsletter.
Company Info
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
Market Cap
$2.0B
Pitch Price
$8.65
Price Target
18.00 (+46%)
Dividend
N/A
EV/EBITDA
-4.35
P/E
-3.98
EV/Sales
22.97
Sector
Biotechnology
Category
growth
Hidden Value: A Deep Dive inside Intellia Therapeutics (NTLA)
NTLA: Pioneering CRISPR co. with 2 Phase 3 trials: NTLA-2002 for HAE, nex-z for ATTR. $862M cash runway to 2027. 27% workforce cut. $9.23/share, $2.13 above cash. Asymmetric risk-reward: $7 downside vs $18-20 upside. Key catalysts: HAELO enrollment (H2 2025), BLA submission (H2 2026).
Read full article (12 min)